相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis
Alejandro Francisco-Cruz et al.
TUBERCULOSIS (2016)
Pneumococcal Adaptive Responses to Changing Host Environments
Anders P. Hakansson
JOURNAL OF INFECTIOUS DISEASES (2014)
Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers
Cesar Enrique Rivas-Santiago et al.
IMMUNOTHERAPY (2013)
Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis
Bruno Rivas-Santiago et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
Bruno Rivas-Santiago et al.
PLOS ONE (2013)
Pattern Recognition Receptors and Cytokines in Mycobacterium tuberculosis Infection-The Double-Edged Sword?
Md Murad Hossain et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Adjunct Immunotherapies for Tuberculosis
Michael Uhlin et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Innate Immune Recognition of Mycobacterium tuberculosis
Johanneke Kleinnijenhuis et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis
C. E. Rivas-Santiago et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Immunogenicity and other problems associated with the use of biopharmaceuticals
Michael G. Tovey et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2011)
Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis
J. Castaneda-Delgado et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Delivery of Therapeutic Proteins
Dipak S. Pisal et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta-analysis and Cost-Effectiveness Study That Focuses on Compliance and Liver Toxicity
Panayiotis D. Ziakas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Therapeutic effect of recombinant adenovirus encoding interferon-γ in a murine model of progressive pulmonary tuberculosis
Dulce A. Mata-Espinosa et al.
MOLECULAR THERAPY (2008)
The potential role of lung epithelial cells and β-defensins in experimental latent tuberculosis
B. Rivas-Santiago et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2008)
β-defensin gene expression during the course of experimental tuberculosis infection
Bruno Rivas-Santiago et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Cutting edge:: Human β defensin 3 -: A novel antagonist of the HIV-1 coreceptor CXCR4
Zhimin Feng et al.
JOURNAL OF IMMUNOLOGY (2006)
Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37
N Mookherjee et al.
JOURNAL OF IMMUNOLOGY (2006)
The human beta-defensin-3, an antibacterial peptide with multiple biological functions
Vishnu Dhople et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2006)
Human beta-defensins
M. Pazgier et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Gutless adenovirus: last-generation adenovirus for gene therapy
R Alba et al.
GENE THERAPY (2005)
Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as immune adjuvant
K Kurosaka et al.
JOURNAL OF IMMUNOLOGY (2005)
A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides
M Carretero et al.
FASEB JOURNAL (2004)
Biology of adenovirus and its use as a vector for gene therapy
MJ McConnell et al.
HUMAN GENE THERAPY (2004)
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection
JM Tufariello et al.
LANCET INFECTIOUS DISEASES (2003)
Defensins: Antimicrobial peptides of innate immunity
T Ganz
NATURE REVIEWS IMMUNOLOGY (2003)
Use of isoniazid for latent tuberculosis infection in a public health clinic
PA LoBue et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
MA Gardam et al.
LANCET INFECTIOUS DISEASES (2003)
A simian replication-defective vaccine to HIV-1 gag
JC Fitzgerald et al.
JOURNAL OF IMMUNOLOGY (2003)
Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2
A Biragyn et al.
SCIENCE (2002)
Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis
AK Arriaga et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Antimicrobial peptides of multicellular organisms
M Zasloff
NATURE (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
How can immunology contribute to the control of tuberculosis?
SHE Kaufmann
NATURE REVIEWS IMMUNOLOGY (2001)
Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis
R Hernández-Pando et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2001)
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology
VP Mohan et al.
INFECTION AND IMMUNITY (2001)
LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells
D Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
